<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688324</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00043248</org_study_id>
    <secondary_id>R03AA019571</secondary_id>
    <nct_id>NCT00688324</nct_id>
  </id_info>
  <brief_title>Biomarker Study of Acamprosate in Schizophrenia</brief_title>
  <official_title>Biomarker Study of Acamprosate in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NMDA receptors are brain receptors that are stimulated by glutamate. Poorly functioning NMDA
      receptors are thought to be involved in the pathology of schizophrenia. This hypothesis is
      based on the observation that PCP, which blocks the NMDA receptor, produces symptoms and
      cognitive impairments similar to schizophrenia. Efforts to enhance the function of the NMDA
      receptor with glycine and D-cycloserine have met with limited success. An alternative
      approach would be to use the drug acamprosate.

      Acamprosate, FDA-approved for maintenance of sobriety after detoxification from alcohol,
      seems to act through modulation of the NMDA receptor. In the lab, acamprosate has been noted
      to act as an antagonist when the NMDA receptors are maximally stimulated but as an agonist
      when NMDA receptor stimulation is minimal. This &quot;smart drug&quot; action makes acamprosate
      appealing for use in schizophrenia. If acamprosate works as a smart drug in patients, then we
      would predict that it would enhance the function of NMDA receptors in schizophrenia and
      improve cognition and the symptoms of the illness. Additionally, acamprosate seems to
      modulate the NMDA receptor in novel ways distinct from glycine and D-cycloserine.

      We will also see if the response to acamprosate differs based on whether participants do or
      do not have a past history of alcohol use disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to measure the response of symptoms and cognition in people schizophrenia given
      acamprosate or placebo. We hypothesize that symptoms and cognition will improve following two
      weeks of acamprosate. We will also use proton magnetic resonance spectroscopy (MRS) to
      examine the effect of acamprosate on glutamate &amp; glutamine (Glu&amp;Gln) brain levels in people
      with schizophrenia. We hypothesize that Glu&amp;Gln concentrations in people with chronic
      schizophrenia will increase following two weeks of treatment with acamprosate.

      The proposed study will consist of 50 individuals with chronic schizophrenia/schizoaffective
      disorder, 18-55 years old, from in/outpatient programs at the Maryland Psychiatric Research
      Center (MPRC). The dose of acamprosate will follow manufacturer recommendations with two
      333mg tablets given three times per day. MRS will be acquired from areas involved in
      schizophrenia [dorsolateral-prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC)] at
      baseline and week two. Symptom ratings and cognitive testing will occur at baseline and be
      repeated at week two.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anterior Cingulate Cortex - Choline</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>Choline brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anterior Cingulate Cortex - Creatinine</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>Creatinine brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anterior Cingulate Cortex - Glutamate</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>Glutamate brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anterior Cingulate Cortex - N-acetylaspartate</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>N-acetylaspartate (NAA) brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anterior Cingulate Cortex - Myo-inositol</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>Myo-inositol brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right Dorsal Lateral Prefrontal Cortex - Choline</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>Choline brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right Dorsal Lateral Prefrontal Cortex - Creatinine</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>Creatinine brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right Dorsal Lateral Prefrontal Cortex - Glutamate</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>Glutamate brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right Dorsal Lateral Prefrontal Cortex - N-acetylaspartate</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>N-acetylaspartate (NAA) brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right Dorsal Lateral Prefrontal Cortex - Myo-inositol</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>Myo-inositol brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Dorsal Lateral Prefrontal Cortex - Choline</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>Choline brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Dorsal Lateral Prefrontal Cortex - Creatinine</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>Creatinine brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Dorsal Lateral Prefrontal Cortex - Glutamate</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>Glutamate brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Dorsal Lateral Prefrontal Cortex - N-acetylaspartate</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>N-acetylaspartate (NAA) brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Dorsal Lateral Prefrontal Cortex - Myo-inositol</measure>
    <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
    <description>Myo-inositol brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fractional Anisotropy Measured With Diffusion Tensor Imaging</measure>
    <time_frame>Completion of two scans</time_frame>
    <description>Diffusion Tensor Imaging Frational Anisotropy (FA) Measures by Lifetime History of Alcohol Abuse/Dependence and Brain Hemisphere.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BPRS - Symptoms of Psychosis Change in Scores</measure>
    <time_frame>Baseline (Treatment Week 0) and End of Study (Treatment Week 2)</time_frame>
    <description>Symptoms of psychosis were measured with the Brief Psychiatric Rating Scale (BPRS). The items rated for psychosis are &quot;Conceptual Disorganization&quot;, &quot;Suspiciousness&quot;, &quot;Hallucinatory Behavior&quot;, and &quot;Unusual Thought Content&quot;. Each item score ranges from &quot;1=Not Present&quot; to &quot;7=Very Severe&quot;.
Value at End of Study minus value at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BPRS - Symptoms of Psychosis Total Score</measure>
    <time_frame>Baseline (Treatment Week 0) and End of Study (Treatment Week 2)</time_frame>
    <description>The psychosis total score is calculated by adding the scores for scales #4 Conceptual Disorganization, #11 Suspiciousness, #12 Hallucinatory Behavior, and #15 Unusual Thought Content. Each scale ranges from &quot;1=Not Present&quot; to &quot;7=Very Severe&quot;. The minimum psychosis score is 4 and the maximum psychosis score is 28. A higher score indicates a more severe psychosis rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SANS - Negative Symptoms of Schizophrenia Total Score</measure>
    <time_frame>Baseline (Treatment Week 0) and End of Study (Treatment Week 2)</time_frame>
    <description>Negative symptoms of schizophrenia measured using the Scale for the Assessment of Negative Symptoms (SANS) Total Score. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment</measure>
    <time_frame>Change from Baseline (Treatment Week 0) to End of Study (Treatment Week 2)</time_frame>
    <description>Cognitive tests will include the DigitSymbol Test (evaluating processing speed), California Verbal Learning Test (CVLTÍ¾ evaluating verbal learning and episodic memory), and NBack (evaluating working memory).
Digit Symbol scaled scores range from 1 to 19, with the larger numbers indicating better performance.
On the CVLT, the delayed recognition score ranges from 0 to 16, with the larger numbers indicating better performance.
On the NBack test, subjects were asked to recall items 0-back, 1-back, and 2-back in a sequence. D-prime scores range from 0 to 8.6. Higher scores are better. As memory load increases from 0 to 1, from 1 to 2, D-prime scores are expected to be lower.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will have baseline measures, receive acamprosate for 2 weeks, then have measures repeated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acamprosate</intervention_name>
    <description>Acamprosate 333mg, ii tablets PO tid x 2 weeks</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Campral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV diagnosis of schizophrenia/schizoaffective disorder

          -  Age 18-55 years

          -  Male or female

          -  Any Race/ethnicity

          -  Participants will be analyzed separately depending on whether they do or do not have a
             history of an alcohol use disorder

        Exclusion Criteria:

          -  Pregnant/nursing females or females not using adequate birth control

          -  Documented history of mental retardation/severe neurological disorder/head injury with
             loss of consciousness

          -  DSM-IV diagnosis of substance dependence in previous six months/abuse in the previous
             three months (except nicotine)

          -  Serious suicidal risk in the previous six months

          -  History of renal failure/creatinine clearance of less than 50mL/min

          -  Current treatment with clozapine

          -  Contraindication to MRI scanning.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard A Fischer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Food and Drug Administration (FDA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Maryland Health Care System</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keypoint Community Mental Health Centers- Dundalk</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keypoint Community Mental Health Centers- Catonsville</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mprc.umaryland.edu/</url>
    <description>Maryland Psychiatric Research Center</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <results_first_submitted>October 24, 2016</results_first_submitted>
  <results_first_submitted_qc>December 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2018</results_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Robert W. Buchanan</investigator_full_name>
    <investigator_title>Chief, Maryland Psychiatric Research Center, Outpatient Research Program</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>schizoaffective disorder</keyword>
  <keyword>glutamate</keyword>
  <keyword>NMDA receptor</keyword>
  <keyword>magnetic resonance spectroscopy</keyword>
  <keyword>acamprosate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acamprosate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were 39 subjects who signed consent for the study. Three subjects were excluded prior to entering the study: two subjects refused to continue and one subject was hospitalized. Thirty six subjects entered the first phase of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Arm</title>
          <description>All subjects will have baseline measures, receive acamprosate for 2 weeks, then have measures repeated.
Acamprosate: Acamprosate 333mg, ii tablets PO tid x 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Baseline Screening</title>
          <description>All subjects will have baseline measures</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Date of birth was not recorded for eight participants who gave consent for screening but did not complete the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Date of birth was not recorded for eight participants who gave consent for screening but did not complete the study.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Abuse History</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anterior Cingulate Cortex - Choline</title>
        <description>Choline brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Subjects entering baseline screening minus the two subjects with missing alcohol abuse history.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Anterior Cingulate Cortex - Choline</title>
          <description>Choline brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Subjects entering baseline screening minus the two subjects with missing alcohol abuse history.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.20"/>
                    <measurement group_id="O2" value="1.54" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="0.18"/>
                    <measurement group_id="O2" value="1.58" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.12"/>
                    <measurement group_id="O2" value="0.04" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anterior Cingulate Cortex - Creatinine</title>
        <description>Creatinine brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Subjects entering baseline screening minus the two subjects with missing alcohol abuse history.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Anterior Cingulate Cortex - Creatinine</title>
          <description>Creatinine brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Subjects entering baseline screening minus the two subjects with missing alcohol abuse history.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.46" spread="0.61"/>
                    <measurement group_id="O2" value="5.12" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.09" spread="0.54"/>
                    <measurement group_id="O2" value="5.16" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.31"/>
                    <measurement group_id="O2" value="0.07" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anterior Cingulate Cortex - Glutamate</title>
        <description>Glutamate brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Subjects entering baseline screening minus the two subjects with missing alcohol abuse history.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Anterior Cingulate Cortex - Glutamate</title>
          <description>Glutamate brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Subjects entering baseline screening minus the two subjects with missing alcohol abuse history.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.44" spread="0.65"/>
                    <measurement group_id="O2" value="6.68" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06" spread="0.78"/>
                    <measurement group_id="O2" value="7.05" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.91"/>
                    <measurement group_id="O2" value="0.26" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anterior Cingulate Cortex - N-acetylaspartate</title>
        <description>N-acetylaspartate (NAA) brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Subjects entering baseline screening minus the two subjects with missing alcohol abuse history.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Anterior Cingulate Cortex - N-acetylaspartate</title>
          <description>N-acetylaspartate (NAA) brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Subjects entering baseline screening minus the two subjects with missing alcohol abuse history.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.40" spread="0.52"/>
                    <measurement group_id="O2" value="5.99" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" spread="0.59"/>
                    <measurement group_id="O2" value="6.14" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.35"/>
                    <measurement group_id="O2" value="0.15" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anterior Cingulate Cortex - Myo-inositol</title>
        <description>Myo-inositol brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Subjects entering baseline screening minus the two subjects with missing alcohol abuse history.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Anterior Cingulate Cortex - Myo-inositol</title>
          <description>Myo-inositol brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Subjects entering baseline screening minus the two subjects with missing alcohol abuse history.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="0.53"/>
                    <measurement group_id="O2" value="4.00" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="0.67"/>
                    <measurement group_id="O2" value="4.35" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.46"/>
                    <measurement group_id="O2" value="0.20" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right Dorsal Lateral Prefrontal Cortex - Choline</title>
        <description>Choline brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Usable scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Right Dorsal Lateral Prefrontal Cortex - Choline</title>
          <description>Choline brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Usable scan data.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.29"/>
                    <measurement group_id="O2" value="1.30" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.17"/>
                    <measurement group_id="O2" value="1.71" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.16"/>
                    <measurement group_id="O2" value="0.40" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right Dorsal Lateral Prefrontal Cortex - Creatinine</title>
        <description>Creatinine brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Usable scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Right Dorsal Lateral Prefrontal Cortex - Creatinine</title>
          <description>Creatinine brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Usable scan data.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.51" spread="0.61"/>
                    <measurement group_id="O2" value="5.48" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.52" spread="0.51"/>
                    <measurement group_id="O2" value="5.54" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.64"/>
                    <measurement group_id="O2" value="0.11" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right Dorsal Lateral Prefrontal Cortex - Glutamate</title>
        <description>Glutamate brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Usable scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Right Dorsal Lateral Prefrontal Cortex - Glutamate</title>
          <description>Glutamate brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Usable scan data.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.89" spread="1.10"/>
                    <measurement group_id="O2" value="7.51" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.63" spread="1.03"/>
                    <measurement group_id="O2" value="7.15" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="1.52"/>
                    <measurement group_id="O2" value="-0.69" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right Dorsal Lateral Prefrontal Cortex - N-acetylaspartate</title>
        <description>N-acetylaspartate (NAA) brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Usable scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Right Dorsal Lateral Prefrontal Cortex - N-acetylaspartate</title>
          <description>N-acetylaspartate (NAA) brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Usable scan data.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.43" spread="0.78"/>
                    <measurement group_id="O2" value="7.65" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.65" spread="0.54"/>
                    <measurement group_id="O2" value="8.15" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.78"/>
                    <measurement group_id="O2" value="0.42" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right Dorsal Lateral Prefrontal Cortex - Myo-inositol</title>
        <description>Myo-inositol brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Usable scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Right Dorsal Lateral Prefrontal Cortex - Myo-inositol</title>
          <description>Myo-inositol brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Usable scan data.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" spread="0.72"/>
                    <measurement group_id="O2" value="3.71" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" spread="0.43"/>
                    <measurement group_id="O2" value="3.44" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.66"/>
                    <measurement group_id="O2" value="-0.24" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Dorsal Lateral Prefrontal Cortex - Choline</title>
        <description>Choline brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Usable scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Left Dorsal Lateral Prefrontal Cortex - Choline</title>
          <description>Choline brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Usable scan data.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.36"/>
                    <measurement group_id="O2" value="1.53" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.20"/>
                    <measurement group_id="O2" value="1.65" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.24"/>
                    <measurement group_id="O2" value="0.10" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Dorsal Lateral Prefrontal Cortex - Creatinine</title>
        <description>Creatinine brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Usable scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Left Dorsal Lateral Prefrontal Cortex - Creatinine</title>
          <description>Creatinine brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Usable scan data.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.38" spread="0.84"/>
                    <measurement group_id="O2" value="5.78" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" spread="1.13"/>
                    <measurement group_id="O2" value="5.86" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.82"/>
                    <measurement group_id="O2" value="0.11" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Dorsal Lateral Prefrontal Cortex - Glutamate</title>
        <description>Glutamate brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Usable scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Left Dorsal Lateral Prefrontal Cortex - Glutamate</title>
          <description>Glutamate brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Usable scan data.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.45" spread="1.21"/>
                    <measurement group_id="O2" value="6.98" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" spread="1.03"/>
                    <measurement group_id="O2" value="6.92" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="1.36"/>
                    <measurement group_id="O2" value="0.03" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Dorsal Lateral Prefrontal Cortex - N-acetylaspartate</title>
        <description>N-acetylaspartate (NAA) brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Usable scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Left Dorsal Lateral Prefrontal Cortex - N-acetylaspartate</title>
          <description>N-acetylaspartate (NAA) brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Usable scan data.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.22" spread="0.99"/>
                    <measurement group_id="O2" value="7.50" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.44" spread="1.25"/>
                    <measurement group_id="O2" value="8.04" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.77"/>
                    <measurement group_id="O2" value="0.16" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Dorsal Lateral Prefrontal Cortex - Myo-inositol</title>
        <description>Myo-inositol brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
        <time_frame>Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)</time_frame>
        <population>Usable scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Left Dorsal Lateral Prefrontal Cortex - Myo-inositol</title>
          <description>Myo-inositol brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in &quot;mM&quot;.</description>
          <population>Usable scan data.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scan 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="0.79"/>
                    <measurement group_id="O2" value="3.61" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scan 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="0.64"/>
                    <measurement group_id="O2" value="4.08" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.97"/>
                    <measurement group_id="O2" value="0.51" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fractional Anisotropy Measured With Diffusion Tensor Imaging</title>
        <description>Diffusion Tensor Imaging Frational Anisotropy (FA) Measures by Lifetime History of Alcohol Abuse/Dependence and Brain Hemisphere.</description>
        <time_frame>Completion of two scans</time_frame>
        <population>Subjects completing study (both scans).</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Anisotropy Measured With Diffusion Tensor Imaging</title>
          <description>Diffusion Tensor Imaging Frational Anisotropy (FA) Measures by Lifetime History of Alcohol Abuse/Dependence and Brain Hemisphere.</description>
          <population>Subjects completing study (both scans).</population>
          <units>FA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right hemisphere</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.03"/>
                    <measurement group_id="O2" value="0.61" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left hemisphere</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.04"/>
                    <measurement group_id="O2" value="0.57" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BPRS - Symptoms of Psychosis Change in Scores</title>
        <description>Symptoms of psychosis were measured with the Brief Psychiatric Rating Scale (BPRS). The items rated for psychosis are &quot;Conceptual Disorganization&quot;, &quot;Suspiciousness&quot;, &quot;Hallucinatory Behavior&quot;, and &quot;Unusual Thought Content&quot;. Each item score ranges from &quot;1=Not Present&quot; to &quot;7=Very Severe&quot;.
Value at End of Study minus value at Baseline.</description>
        <time_frame>Baseline (Treatment Week 0) and End of Study (Treatment Week 2)</time_frame>
        <population>Subjects completing the BPRS rating at Baseline and End of Study.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>BPRS - Symptoms of Psychosis Change in Scores</title>
          <description>Symptoms of psychosis were measured with the Brief Psychiatric Rating Scale (BPRS). The items rated for psychosis are &quot;Conceptual Disorganization&quot;, &quot;Suspiciousness&quot;, &quot;Hallucinatory Behavior&quot;, and &quot;Unusual Thought Content&quot;. Each item score ranges from &quot;1=Not Present&quot; to &quot;7=Very Severe&quot;.
Value at End of Study minus value at Baseline.</description>
          <population>Subjects completing the BPRS rating at Baseline and End of Study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Conceptual Disorganization Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.182" spread="0.603"/>
                    <measurement group_id="O2" value="0.0" spread="0.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suspiciousness Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.636" spread="2.111"/>
                    <measurement group_id="O2" value="-0.532" spread="1.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hallucinations Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0909" spread="1.7581"/>
                    <measurement group_id="O2" value="-0.6250" spread="1.3102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual Thought Content Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0909" spread="1.1362"/>
                    <measurement group_id="O2" value="-0.1250" spread="0.7188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BPRS - Symptoms of Psychosis Total Score</title>
        <description>The psychosis total score is calculated by adding the scores for scales #4 Conceptual Disorganization, #11 Suspiciousness, #12 Hallucinatory Behavior, and #15 Unusual Thought Content. Each scale ranges from &quot;1=Not Present&quot; to &quot;7=Very Severe&quot;. The minimum psychosis score is 4 and the maximum psychosis score is 28. A higher score indicates a more severe psychosis rating.</description>
        <time_frame>Baseline (Treatment Week 0) and End of Study (Treatment Week 2)</time_frame>
        <population>Subjects completing BPRS rating at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>BPRS - Symptoms of Psychosis Total Score</title>
          <description>The psychosis total score is calculated by adding the scores for scales #4 Conceptual Disorganization, #11 Suspiciousness, #12 Hallucinatory Behavior, and #15 Unusual Thought Content. Each scale ranges from &quot;1=Not Present&quot; to &quot;7=Very Severe&quot;. The minimum psychosis score is 4 and the maximum psychosis score is 28. A higher score indicates a more severe psychosis rating.</description>
          <population>Subjects completing BPRS rating at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.88" spread="3.77"/>
                    <measurement group_id="O2" value="9.47" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.82" spread="4.14"/>
                    <measurement group_id="O2" value="8.38" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="3.95"/>
                    <measurement group_id="O2" value="-1.31" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SANS - Negative Symptoms of Schizophrenia Total Score</title>
        <description>Negative symptoms of schizophrenia measured using the Scale for the Assessment of Negative Symptoms (SANS) Total Score. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms.</description>
        <time_frame>Baseline (Treatment Week 0) and End of Study (Treatment Week 2)</time_frame>
        <population>Subjects completing the SANS assessment at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>SANS - Negative Symptoms of Schizophrenia Total Score</title>
          <description>Negative symptoms of schizophrenia measured using the Scale for the Assessment of Negative Symptoms (SANS) Total Score. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms.</description>
          <population>Subjects completing the SANS assessment at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.50" spread="10.73"/>
                    <measurement group_id="O2" value="26.12" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.18" spread="12.09"/>
                    <measurement group_id="O2" value="26.38" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.091" spread="8.384"/>
                    <measurement group_id="O2" value="-0.375" spread="6.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Impairment</title>
        <description>Cognitive tests will include the DigitSymbol Test (evaluating processing speed), California Verbal Learning Test (CVLTÍ¾ evaluating verbal learning and episodic memory), and NBack (evaluating working memory).
Digit Symbol scaled scores range from 1 to 19, with the larger numbers indicating better performance.
On the CVLT, the delayed recognition score ranges from 0 to 16, with the larger numbers indicating better performance.
On the NBack test, subjects were asked to recall items 0-back, 1-back, and 2-back in a sequence. D-prime scores range from 0 to 8.6. Higher scores are better. As memory load increases from 0 to 1, from 1 to 2, D-prime scores are expected to be lower.</description>
        <time_frame>Change from Baseline (Treatment Week 0) to End of Study (Treatment Week 2)</time_frame>
        <population>Subjects who completed cognitive testing at both study time points.</population>
        <group_list>
          <group group_id="O1">
            <title>ETOH Abuse</title>
            <description>Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
          <group group_id="O2">
            <title>No ETOH Abuse</title>
            <description>No Lifetime History of Alcohol Abuse/Dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Impairment</title>
          <description>Cognitive tests will include the DigitSymbol Test (evaluating processing speed), California Verbal Learning Test (CVLTÍ¾ evaluating verbal learning and episodic memory), and NBack (evaluating working memory).
Digit Symbol scaled scores range from 1 to 19, with the larger numbers indicating better performance.
On the CVLT, the delayed recognition score ranges from 0 to 16, with the larger numbers indicating better performance.
On the NBack test, subjects were asked to recall items 0-back, 1-back, and 2-back in a sequence. D-prime scores range from 0 to 8.6. Higher scores are better. As memory load increases from 0 to 1, from 1 to 2, D-prime scores are expected to be lower.</description>
          <population>Subjects who completed cognitive testing at both study time points.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in NBack 0-Back Total Hits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="1.886"/>
                    <measurement group_id="O2" value="0.214" spread="1.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in NBack 1-Back Total Hits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="3.20"/>
                    <measurement group_id="O2" value="1.14" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in NBack 2-Back Total Hits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="2.41"/>
                    <measurement group_id="O2" value="1.71" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in DigitSymbol Scaled Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="1.03"/>
                    <measurement group_id="O2" value="0.00" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CVLT Total Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.600" spread="1.955"/>
                    <measurement group_id="O2" value="-0.143" spread="1.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Overall study of 6 weeks.</time_frame>
      <desc>Reportable adverse events (AEs) are defined as any harm experienced by a study participant, which in the opinion of the investigator is unexpected and probably related to the research procedures. None of our AEs met these criteria.
Participants are systematically monitored for any increases the Side Effects Checklist (SEC). An SEC AE includes any symptom/side effect rated with a score of 4 (severe) or for which there was a 2 point change in severity from baseline.</desc>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>All subjects will have baseline measures, receive acamprosate for 2 weeks, then have measures repeated.
Acamprosate: Acamprosate 333mg, ii tablets PO tid x 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Perceived increase in essential tremor</sub_title>
                <description>Subject had a perceived increase in their essential tremor that they attributed to the study medication. Subject refused to continue participation.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Claustrophobia in MRI scan</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Subject became claustrophobic in the MRI scanner. Refused to continue participation.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert W. Buchanan, M.D.</name_or_title>
      <organization>Maryland Psychiatric Research Center</organization>
      <phone>410-402-7876</phone>
      <email>rwbuchanan@som.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

